Johnson & Johnson (JNJ) demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. ROIV
6. AAPL
7. ACN
8. AZN
9. ORCL
10. HOOD

Go back to Johnson & Johnson (JNJ) demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
Johnson & Johnson (NYSE: JNJ) Delayed: 270.74 -4.49 (1.63%)
Previous Close $275.23    52 Week High $126.07 
Open $271.28    52 Week Low $94.28 
Day High $271.99    P/E 56.29 
Day Low $266.88    EPS $4.81 
Volume 4,324,626